Defence Therapeutics Inc. (OTCMKTS:DTCFF) Short Interest Down 5.9% in June

Defence Therapeutics Inc. (OTCMKTS:DTCFF) was the recipient of a large decrease in short interest during the month of June. As of June 15th, there was short interest totalling 1,600 shares, a decrease of 5.9% from the May 31st total of 1,700 shares. Based on an average trading volume of 1,300 shares, the days-to-cover ratio is currently 1.2 days.

Defence Therapeutics Price Performance

Shares of OTCMKTS DTCFF opened at $0.62 on Wednesday. The stock has a 50 day moving average price of $0.84 and a 200 day moving average price of $1.22. Defence Therapeutics has a 52 week low of $0.57 and a 52 week high of $3.19.

Defence Therapeutics Company Profile

Defence Therapeutics Inc engages in development of a biological drug enhancer platform that improves the efficacy and safety of a multitude of biological/biosimilar based pharmaceuticals used in the treatment of cancer and infectious diseases. The company focuses on development of vaccine for infectious disease and virus utilizing the ACCUMTM platform for drug delivery and effective treatments.